Intellia Therapeutics, Inc.’s Post

✔️ Looks like it was a great week in Liverpool from the feedback - Lots of change since I last attended the BioIndustry Association (BIA) BioprocessUK at the Manchester Midland, just before I moved to India. ⏳ The big subjects then were protein therapeutic processing and the importance of yield, stability, and aggregation. The focus has shifted since then to Gene & Cell Therapies, as you might expect - how to process and manufacture these innovative medicines more efficiently to maximise patient-benefit. 🧬 Whether it be mAbs or Gene Therapies, or any of the other cutting-edge modalities being developed to improve health, Malvern Panalytical Pharmaceuticals has the biophysical tech and knowledge to de-risk and speed up your development processes. For more, please see here: https://lnkd.in/gj57ZxMi #CGT #BioprocessUK #mAb #Biologics

Customizable dashboards, real-time shipment data, detailed analytics and more. OCELLOS is the ultimate cell and gene therapy supply chain solution. Book a demo with one of our experts to learn more: https://loom.ly/XvieiLU Attending Advanced Therapies Congress next week? See OCELLOS in action at our stand: 209. #CGT #CellAndGeneTherapy #SupplyChain #SupplyChainAutomation #CGTSupplyChain #PersonalizedMedicine

Today’s the day! Join us at 1:00 PM EST for our webinar, "Introduction to the Gene and Cellular Therapy Era." We’ll explore the latest advancements, innovative payment models, and the challenges gene and cellular therapies bring to healthcare. There’s still time to register—don’t miss out on this important conversation! https://bit.ly/47EkSEw #ElevatingSpecialtyPharmay #ShieldsRx

Interested in learning how the #AdvancedTherapies industry can enhance today's manufacturing practices to establish fully automated, digitally integrated processes? ➡️ https://buff.ly/3BthKPL Daniel Gibson, Head of Collaborations at the Cell and Gene Therapy Catapult, highlights this and more in his key takeaways from Phacilitate's recent Advanced Therapies Europe event. Read the blog ☝️ #CellTherapy #GeneTherapy #ATMPs

Have you had a chance to explore our recent whitepapers? Would you like to revisit the ones that caught your attention? Over the last four weeks, we published four whitepapers looking at a different aspect of how #DecentralizedManufacturing of cell and gene therapies can be achieved and used to increase accessibility for rural and global communities. You can read the entire series here: www.realm.bio/insights A BIG thank you to everyone who collaborated with us and helped to create this series! Domhnall Mc Gowan, Erika Francoeur, Craig Hasilo, Jenny Ligon, Stephen Stewart, and Enayat Mohammad, PMP

Join us on Tuesday, October 22nd, from 1:00 to 2:00 PM EST for our webinar, "Introduction to the Gene and Cellular Therapy Era." This session will explore the unique challenges these therapies present in healthcare delivery and the innovative solutions emerging in response. Register now to deepen your understanding of current FDA-approved therapies, operational considerations, and evolving payment models. Don’t miss this opportunity to be part of this transformative discussion! https://bit.ly/47EkSEw #ElevatingSpecialtyPharmacy #ShieldsRx

So excited to share this Cencora white paper titled "Unraveling Payer Trends" (authored and led by Shaila Yoshida) as a consolidated resource of market research we've conducted over the past ~1 year. This includes >20 posters on value assessments, management of cell and gene therapies, opinions on PIE, use of AI in lit reviews, early access programs in the EU and more! Very cool to see findings from numerous research projects completed by my colleagues and I!! ▶ Follow this link to access the report: https://lnkd.in/ezeeDUPh

Consider this 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗴𝗮𝗶𝗻 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀 that will drive the 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀. My presentation will focus on setting apart your therapy for payers through science. My panel will discuss strategies for cross-functional collaboration. 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗴𝗲𝗻𝗱𝗮 𝗵𝗲𝗿𝗲 – https://ter.li/lhvjuu

Coeptis is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh, SNAP-CAR. Coeptis is also developing GEAR, a gene editing technology used to develop antibody resistant effector cell with VyGen-Bio, a wholly owned subsidiary of Vycellix and researchers at the Karolinska Institute. Dive into the promise of #celltherapy: https://bit.ly/3V6hoGu

Don't forget to sign up for the Biophysical Summit hosted by Applied Photophysics and KBI Biopharma! 🏔 This summit will highlight some of the latest analytical techniques for developing and characterizing protein and gene therapies. Come with your questions and learn how companies tackle the characterization of novel modalities! Register here: https://bit.ly/3TxZawo #BiophysicalSummit #KBI #AppliedPhotophysics